Intervention not reported
Complete or partial remission ( · patients with primary nephrotic syndrome
The intervention showed no clear difference in complete or partial remission ( (low certainty).
1 finding from 1 review
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
CHM may leads to higher total effectiveness rate (Analysis 1.1) Clinician's rating compared with placebo (low certainty).
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
CHM may leads to lower adverse events (Analysis 2.6) Participant's reports compared with drugs (low certainty).
1 finding from 1 review
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
Combination of oral and topical CHM showed no clear difference in total effectiveness rate (Analysis 3.1) Clinician's rating compared with same oral CHM (low certainty).
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
QoL · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
Combination of oral and topical CHM showed no clear difference in adverse events (Analysis 3.7) Participant's report compared with same oral CHM (low certainty).
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Skin lesion score (Analysis 3.4) Clinician's rating. Scale from 0 to 24 · atopic eczema
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
QoL · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
CHM showed no clear difference in adverse events (Analysis 1.7) Participant's report compared with placebo (low certainty).
1 finding from 1 review
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
It is very uncertain whether CHM changes total effectiveness rate (Analysis 2.1) Clinician's rating compared with drugs (very low certainty).
1 finding from 1 review
Total effectiveness rate with subgroup analysis ‐ individualised treatment Clinician's rating · atopic eczema
CHM may leads to higher total effectiveness rate with subgroup analysis ‐ individualised… compared with drugs (low certainty).
1 finding from 1 review
Total effectiveness rate with subgroup analysis ‐ non‐individualised treatment Clinician's rating · atopic eczema
It is very uncertain whether CHM changes total effectiveness rate with subgroup analysis ‐ non‐individualised… compared with drugs (very low certainty).
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Intervention not reported
Death from any cause · participants with hypertriglyceridaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cardiovascular or cerebrovascular events · participants with hypertriglyceridaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found